Compare Gilead Sciences, Inc. (GILD) vs Upstart Holdings Inc (UPST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Upstart Holdings Inc — how do they compare? Gilead Sciences, Inc. trades at $135.59 (market cap $163.51B), while Upstart Holdings Inc trades at $30.82 (market cap $3.02B). The key difference: Gilead Sciences, Inc. is far larger — about 54.1× Upstart Holdings Inc's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while Upstart Holdings Inc pays none. Which is the better fit depends on your goals.
| GILD | UPST | |
|---|---|---|
Market Cap | $163.51B | $3.02B |
Sector | Health | Financials |
52-Week High | $155.80 | $84.13 |
52-Week Low | $108.22 | $24.22 |
Enterprise Value | $178.05B | — |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Upstart Holdings (UPST) trades at $30.86, down 2.71% today, with a bearish technical signal from moving averages but oversold RSI conditions. The company reported a return to profitability in 2025 with $1.02B revenue and $53.60M net income, though recent Q1 2026 earnings missed expectations. Analyst sentiment is divided with a $42.00 consensus price target, while cash flow trends show improved but still negative operational cash generation.
UPST presents a high-risk, high-reward opportunity with strong AI lending growth potential but faces execution risks and margin pressure. The stock's current valuation at 77x P/E demands flawless execution of expansion into auto and home loans. Near-term performance hinges on Q2 2026 results due August 4, 2026, with investors watching for sustained profitability and funding stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Upstart Holdings Inc
Upstart Holdings Inc provides credit services. The company provides a proprietary, cloud-based, artificial intelligence lending platform. The platform aggregates consumer demand for loans and connects it to the network of Upstart AI-enabled bank partners. The revenue of the company is primarily comprised of fees paid by banks.
Read more on UPST →
